141 related articles for article (PubMed ID: 21495997)
1. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
2. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
3. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
4. Complete response in a melanoma patient treated with imatinib.
Brown MC; Casasola RJ
J Laryngol Otol; 2012 Jun; 126(6):638-40. PubMed ID: 22643209
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
Lutzky J; Bauer J; Bastian BC
Pigment Cell Melanoma Res; 2008 Aug; 21(4):492-3. PubMed ID: 18510589
[No Abstract] [Full Text] [Related]
6. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
7. c-kit gene mutation and CD117 expression in human anorectal melanomas.
Ni S; Huang D; Chen X; Huang J; Kong Y; Xu Y; Du X; Sheng W
Hum Pathol; 2012 Jun; 43(6):801-7. PubMed ID: 22154054
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
10. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of KIT in melanoma.
Postow MA; Carvajal RD
Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014
[TBL] [Abstract][Full Text] [Related]
12. Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC; Bröcker EB; Schadendorf D; Ugurel S
J Clin Oncol; 2007 Mar; 25(7):e9. PubMed ID: 17327598
[No Abstract] [Full Text] [Related]
13. Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
[No Abstract] [Full Text] [Related]
14. V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
McDonnell K; Betz B; Fullen D; Lao CD
Pigment Cell Melanoma Res; 2011 Apr; 24(2):390-2. PubMed ID: 21159146
[No Abstract] [Full Text] [Related]
15. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
16. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
17. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
Cairoli R; Beghini A; Morello E; Grillo G; Montillo M; Larizza L; Morra E
Leuk Res; 2005 Apr; 29(4):397-400. PubMed ID: 15725473
[TBL] [Abstract][Full Text] [Related]
19. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations.
Schoenewolf NL; Bull C; Belloni B; Holzmann D; Tonolla S; Lang R; Mihic-Probst D; Andres C; Dummer R
Eur J Cancer; 2012 Aug; 48(12):1842-52. PubMed ID: 22464346
[TBL] [Abstract][Full Text] [Related]
20. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
